1802220-02-5 Usage
Description
Ropotrectinib (TPX-0005; TP Therapeutics, San Diego, CA, USA) is a nextgeneration ROS1 inhibitor, a novel three-dimensional macrocyle with a much
smaller size (MW <370) than current ROS1 inhibitors. It was specifically
designed to overcome resistance mutations. Preclinical studies have shown activity
against gatekeeper and solvent mutations, including G2032R, D2033N, L2026M,
S1986F/Y, L1951R, and kinases involved in bypass signaling such as focal adhesion
kinase, SRC proto-oncogene, and non-receptor tyrosine kinase [102, 103].
Check Digit Verification of cas no
The CAS Registry Mumber 1802220-02-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,2,2,2 and 0 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1802220-02:
(9*1)+(8*8)+(7*0)+(6*2)+(5*2)+(4*2)+(3*0)+(2*0)+(1*2)=105
105 % 10 = 5
So 1802220-02-5 is a valid CAS Registry Number.
1802220-02-5Relevant articles and documents
Macrocyclic compounds
-
, (2019/12/29)
The invention discloses compounds represented by formula (I), or pharmaceutically acceptable salts thereof, and also relates to a preparation method of the compounds represented by formula (I) or thepharmaceutically acceptable salts thereof, a medicinal composition containing the compounds represented by formula (I) or the pharmaceutically acceptable salts thereof, and a use of the compounds represented by formula (I) or the pharmaceutically acceptable salt thereof. R1 and R2 in the formula (I) are as defined in the present application.
CHIRAL DIARYL MACROCYCLES AND USES THEREOF
-
, (2017/03/08)
This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. T
